SecSonar.com

Atai Beckley N.V (ATAI)

Atai Beckley N.V at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Atai Beckley N.V (ATAI) is a Biotechnology company based in US with a market capitalization of $1.7B. Revenue grew 1227.6% year-over-year and free cash flow was negative at -$103.6M. This page tracks ATAI's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 99 employees · IPO Jun 18, 2021

Valuation

Valuation & price

$4.25 · as of May 26, 2026 · -34.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.53

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.22$4.42$2.62Jul 25Dec 25Jul 26Jul 7, 25$2.75Jul 9, 25$2.66Jul 11, 25$2.62Jul 15, 25$2.65Jul 17, 25$2.79Jul 21, 25$3.53Jul 23, 25$3.88Jul 25, 25$3.57Jul 29, 25$3.31Jul 31, 25$4.10Aug 4, 25$4.26Aug 6, 25$4.19Aug 11, 25$3.96Aug 13, 25$4.05Aug 15, 25$3.88Aug 19, 25$3.97Aug 21, 25$4.39Aug 25, 25$4.74Aug 27, 25$4.57Aug 29, 25$4.58Sep 3, 25$4.52Sep 5, 25$4.57Sep 9, 25$4.89Sep 11, 25$4.60Sep 16, 25$4.65Sep 18, 25$4.72Sep 22, 25$4.88Sep 24, 25$5.49Sep 26, 25$5.27Sep 30, 25$5.29Oct 2, 25$5.14Oct 6, 25$5.47Oct 8, 25$5.58Oct 10, 25$5.10Oct 14, 25$6.00Oct 16, 25$5.48Oct 21, 25$5.87Oct 23, 25$5.55Oct 27, 25$6.22Oct 29, 25$5.86Oct 31, 25$5.84Nov 4, 25$5.28Nov 6, 25$4.34Nov 10, 25$4.35Nov 12, 25$4.33Nov 14, 25$4.00Nov 18, 25$3.93Nov 20, 25$3.66Nov 25, 25$3.76Nov 28, 25$3.89Dec 2, 25$3.87Dec 4, 25$4.40Dec 8, 25$4.45Dec 10, 25$4.33Dec 12, 25$4.29Dec 16, 25$4.23Dec 18, 25$3.91Dec 22, 25$4.30Dec 24, 25$4.19Dec 29, 25$4.00Jan 2, 26$3.87Jan 6, 26$4.00Jan 8, 26$3.97Jan 12, 26$3.76Jan 14, 26$3.72Jan 16, 26$3.64Jan 21, 26$3.90Jan 23, 26$4.15Jan 27, 26$3.90Jan 29, 26$3.84Feb 2, 26$3.84Feb 4, 26$3.61Feb 9, 26$3.94Feb 11, 26$3.97Feb 13, 26$3.57Feb 18, 26$3.95Feb 20, 26$3.88Feb 24, 26$4.37Feb 26, 26$3.73Mar 2, 26$3.68Mar 4, 26$3.69Mar 6, 26$3.39Mar 10, 26$4.14Mar 12, 26$3.82Mar 17, 26$3.65Mar 19, 26$3.57Mar 23, 26$3.39Mar 25, 26$3.54Mar 27, 26$3.35Mar 31, 26$3.54Apr 2, 26$3.79Apr 7, 26$3.79Apr 9, 26$3.70Apr 13, 26$3.79Apr 15, 26$4.00Apr 17, 26$4.03Apr 22, 26$4.71Apr 24, 26$4.63Apr 28, 26$4.33Apr 30, 26$4.16May 4, 26$4.20May 6, 26$4.17May 8, 26$4.03May 12, 26$4.15May 14, 26$4.04May 18, 26$4.15May 20, 26$4.09May 22, 26$4.32May 28, 26$4.41Jun 1, 26$4.82Jun 3, 26$4.53Jun 5, 26$3.95Jun 9, 26$3.89Jun 11, 26$3.80Jun 15, 26$3.84Jun 17, 26$4.07Jun 22, 26$4.05Jun 24, 26$4.17Jun 26, 26$5.29Jul 2, 26$5.19
$2.6252-week range$6.45
Loading valuation history…

Fundamentals

Key fundamentals

$1.7B

Market cap

1227.6%

Revenue growth (YoY)

75.3%

Gross margin

-$103.6M

Free cash flow (USD)

-$254M

Net debt

Net cash position

41.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2019 → 2025

FY 2019$0.00FY 2020$0.00FY 2021$20.4MFY 2022$233.0KFY 2023$314.0KFY 2024$308.0KFY 2025$4.1M
$0$4.1M

Free cash flow by year

2019 → 2025

FY 2019$-7.9MFY 2020$-20.8MFY 2021$-64.4MFY 2022$-105.5MFY 2023$-84.7MFY 2024$-82.5MFY 2025$-103.6M
-$7.9M-$103.6M

Gross margin by year

2021 → 2025

FY 202199.8%FY 202227.9%FY 2023-1.6%FY 2024-53.6%FY 202575.3%
99.8%75.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

2

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $250K · 10b5-1 PlanKochendoerfer Gerd · Chief Operating Officer · $250KJun 29, 2026Filing
  • Insider sellInsider Sell $192K · 10b5-1 PlanCraig Kevin James · Chief Medical Officer · $192KJun 29, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 8, 2026Filing
  • 8-K eventInvestor Conference ParticipationJun 3, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing

Questions

Frequently asked questions

What is Atai Beckley N.V's market cap?

Atai Beckley N.V (ATAI) has a market capitalization of $1.7B.

What is ATAI's P/E ratio?

A meaningful P/E ratio is not available for ATAI — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ATAI's price-to-book (P/B) ratio?

ATAI trades at 7.53 times book value per share.

Are insiders buying ATAI stock?

SEC Form 4 filings show no open-market insider buys at Atai Beckley N.V in the last 90 days (2 sells).

Same arena

Related companies in Biotechnology

OCS

Oculis Holding AG

$1.7B

NUVB

Nuvation Bio Inc.

$1.6B

VCEL

Vericel Corporation

$1.7B

VIR

Vir Biotechnology, Inc.

$1.6B

SNDX

Syndax Pharmaceuticals, Inc.

$1.7B

RXRX

Recursion Pharmaceuticals, Inc.

$1.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.